DetraPel Inc.
United States
- Framingham, Massachusetts
- 12/09/2023
- Series A
- $7,600,000
Parent Company of our Industrial Vertical, Impermea Materials & Consumer Brand, ProofPlus™.
Leading innovation in surface protection. Committed to sustainability. Join us in shaping a resilient, eco-friendly future.
- Industry Chemical Manufacturing
- Website N/A
- LinkedIn https://www.linkedin.com/company/detrapel/about/
Related People
David ZamarinFounder
United States -
Boston, Massachusetts
Driven by an urgency to create a better future for my generation and future generations, I founded DetraPel with one simple mission to #protectwhatyoulove. This mission is derived from my passions for entrepreneurship and creating world-changing initiatives that contribute to a thriving society and planet.
I believe that through innovation and a commitment to reduce environmental impacts and negative health effects, corporations have the power and responsibility to disrupt the growing trajectory of global challenges. That is why I have implemented a strategic shift towards a smarter business model that reimagines the way my company builds new consumer and industrial products, creates distinction and contributes to change.
Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)